Mauna Kea Technologies | |
Stock Exchange | Euronext Paris |
EPS |
EUR0.51 |
Market Cap |
EUR46.17 M |
Shares Outstanding |
23.15 M |
Public Float |
21.48 M |
Address |
9, rue d'Enghien Paris Ile-de-France 75010 France |
Employees | - |
Website | http://www.maunakeatech.com |
Updated | 07/08/2019 |
Mauna Kea Technologies SA is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases. The company engages in the design, development, and sale of optical biopsy devices and tools to visualize and detect abnormalities in the gastro-intestinal and pulmonary tracts primarily in cancer patients. Its product, Cellvizio, a probe-based Confocal Laser Endomicroscopy system, provides physicians and researchers high resolution cellular views of tissue inside the body. |